Scientific evidence in the doctor's practice: 10 Theses about the effectiveness and good tolerance of a treatment with glitazones;Wissenschaftliche evidenz in der ärztlichen praxis: 10 Thesen zur wirksamkeit und verträglichkeit einer therapie mit glitazonen

Diabetes, Stoffwechsel und Herz

Volumn 15, Issue 6, 2006, Pages 94-98

  Daikeler, Richard ^a   Erdmann, Erland ^a   Forst, Thomas ^a   Lederle, Martin ^a   Pfützner, Andreas ^a   Rothe, Ulrike ^a   Schneider, Christian ^a   Schnell, Oliver ^a   Schulze, Jan ^a   Standl, Eberhard ^a   Tschöpe, Carsten ^a   Tschöpe, Diethelm ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

ARTERIOSCLEROSIS; DIABETIC PATIENT; DRUG EFFICACY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GERMANY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TREATMENT RESPONSE;

EID: 57149112517     PISSN: 18617603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Aronoff S et al.: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6 month randomised placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-1611
2. Bakris G et al.: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertension 2003; 17: 7-12
3. Belcher G et al.: Cardiac safety of pioglitazone in comparison with metformin and gliclazide. Int J Clin Pract 2005; 58: 833-837
4. Belcher G et al.: Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabetes Med 2005; 8: 973-979
5. Campia U et al.: Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in non-diabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867-875
6. Ceriello A et al.: Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28: 266-272
7. Charbonnel B et al.: Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparison with gliclazide-based regimens. Diabetologia 2005; 48: 553-560
8. Charbonnel B et al.: Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005; 48: 1093-1104
9. Charbonnel B et al.: A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus : a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005; 22: 399-405
10. Choi D et al.: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-2660
11. Chu JW et al.: Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab Vasc Dis Res 2005; 2: 37-41
12. Derosa G et al.: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28: 917-924
13. Derosa G et al.: Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab 2006; 8: 197-205
14. Dormandy JA et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289
15. Durbin RJ: Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6: 280-285
16. Esposito K et al.: Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006; 29: 1071-1076
17. Fachinformation Actos, 2005
18. Fachinformation Avandia, 2005
19. Freed MI et al.: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-952
20. Füllen S et al.: Effects of pioglitazone in non-diabetic patients with arterial hypertension: a double-blind placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503-5506
21. Goldberg RB et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554
22. Haffner SM et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684
23. Hanefeld M et al.: One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-147
24. Hanefeld M et al.: Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076
25. Hanefeld M et al.: Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin 2006; 22: 1211-1215
26. Hetzel J et al.: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005; 25: 1804-1809
27. Jin J et al. : Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance. Diabetes Res Clin Pract 2006, available online 9 June 2006
28. Juhl CB et al.: Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin. J Clin Endocrinol Metab 2003; 88: 3794-3800
29. Knowler WC et al.: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150-1156
30. Koshiyama H et al.: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456
31. Kubo K: Effect of pioglitazone on fibrinolytic factors and markers of vascular endothelial function in patients with type 2 diabetes. J Japan Soc 2001; 44: 687-692
32. Kubo K: Effect of pioglitazone on blood pro-insulin levels in patients with type 2 diabetes mellitus. Endocr J 2002; 49: 323-328
33. Langenfeld MR et al.: Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-2531
34. Lawrence JM et al.: Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004; 27: 41-46
35. Lebovitz HE et al.: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288
36. Majali KA et al.: The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism , lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 2006; 49: 527-537
37. Marx N et al.: Antidiabetic PPAR-gamma activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288
38. Marx N et al.: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-1957
39. Marx N et al.: Pioglitazone reduces neointima formation after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in non-diabetic patients. Circulation 2005; 112: 2792-2798
40. Masoudi FA et al.: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure. Circulation 2005; 111: 583-590
41. Meisner F et al.: Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol 2006; 26: 845-850
42. Miyazaki Y et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrin Metab 2002; 87: 2784-2791
43. Nakamura T et al.: Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000; 14: 250-254
44. Nakamura T et al.: Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50: 1193-1196
45. Nakamura T et al.: Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53: 1382-1386
46. Natali A et al.: Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27: 1349-1357
47. Negro R et al.: Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005; 70: 20-25
48. Nishio K et al.: A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006; 29: 101-106
49. Ovalle F et al.: Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004; 27: 2585-2589
50. Pavo I et al.: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 1637-1645
51. Pistrosch F et al.: In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dsyfunction independent of glucose control. Diabetes Care 2004; 27: 484-490
52. Pistrosch F et al.: Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54: 2206-2211
53. Pfützner A et al.: Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab 2005; 37: 510-515
54. Pfützner A et al.: IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. Diabetes Technol Ther 2005; 7: 478-486
55. Pfützner A et al.: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931
56. Pfützner A et al.: Impact of Rosiglitazone on β-Cell Function, Insulin Resistance and Adiponektin Concentrations - Results from a Double Blind Oral Combination Study with Glimepiride. Metabolism 2006; 55: 20-25
57. Pfützner A et al.: Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther 2006; 4: 445-459
58. Raji A et al.: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-178
59. Roden M et al.: Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with type 2 diabetes mellitus. Diabet Med 2005; 22: 1101-1106
60. Sarafidis PA et al.: Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004; 22: 1769-1777
61. Satoh N et al.: Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499
62. Schernthaner G et al.: Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076
63. Sidhu JS et al.: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-1763
64. Sidhu JS et al.: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-934
65. St John Sutton M et al.: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-2064
66. Szapary PO et al.: Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 182-188
67. Tan MH et al.: Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Curr Med Res Opin 2004; 20: 723-728
68. Tan MH et al.: Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycemic control, and lipid profiles in patients with type 2 diabetes. Diabet Med 2004; 21: 859-866
69. Tan MH et al.: Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005; 28: 544-540
70. The DREAM Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105
71. Wang G et al.: Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 2005; 54: 590-597
72. Winkler K et al.: Pioglitazone reduces atherogenic dense low density LDL lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2002; 2: 143-148
73. Winkler K et al.: Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003; 26: 2588-2594
74. Xiang AH et al.: Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517-522